In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained ...
Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...
CAR-T therapy delivered significant clinical improvements in adults with stiff person syndrome (SPS) in the pivotal ...
CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...
A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...
MedPage Today on MSN
CAR-T trial raises prospect of preventing myeloma in high-risk group
All 20 smoldering myeloma patients had deep responses after one-time infusion ...
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...
During a live event, Binod Dhakal, MD, discussed the rationale for choosing therapy given before CAR T-cell infusion in multiple myeloma.
The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen ...
Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...
CAR-T cell therapy has spread into earlier lines of care over the last ten years, going beyond heavily pretreated populations ...
Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana is offering a CAR-T cell-based immunotherapy, which genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results